Neurociencia del consumo y dependencia de sustancias psicoactivas
Neurociencia del consumo y dependencia de sustancias psicoactivas Neurociencia del consumo y dependencia de sustancias psicoactivas
5. BASES GENÉTICAS DE LAS FARMACODEPENDENCIASshow no association with smoking initiation or nicotine dependence. AmericanJournal of Medical Genetics, 96:646–653.Singleton AB y colab. (1998) Lack of association between the dopamine D2receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population.Pharmacogenetics, 8:125–128.Slutske WS y colab. (1999) The heritability of alcoholism symptoms: "indicatorsof genetic and environmental influence in alcohol-dependent individuals" revisited.Alcoholism: Clinical and Experimental Research, 23:759–769.Spergel DJ y colab. (2001) Using reporter genes to label selected neuronal populationsin transgenic mice for gene promoter, anatomical, and physiologicalstudies. Progress in Neurobiology, 63:673–686.Stallings MC y colab. (1999) A twin study of drinking and smoking onset andlatencies from first use to regular use. Behavior Genetics, 29:409–421.Stoltenberg SF, Burmeister M (2000) Recent progress in psychiatric genetics —some hope but no hype. Human Molecular Genetics, 9:927–935.Straub RE y colab. (1999) Susceptibility genes for nicotine dependence: agenome scan and follow up in an independent sample suggest that regions onchromosomes 2, 4, 10, 16, 17 and 18 merit further study. Molecular Psychiatry,4:129–144.Sullivan PF, Kendler KS (1999) The genetic epidemiology of smoking. Nicotineand Tobacco Research, 1(Suppl. 2):S51–S57; S69–S70.Sullivan PF y colab. (2001) Association of the tryptophan hydroxylase gene withsmoking initiation but not progression to nicotine dependence. AmericanJournal of Medical Genetics, 105:479–484.Sun F y colab. (1999) Association of genetic polymorphisms of alcohol-metabolizingenzymes with excessive alcohol consumption in Japanese men. HumanGenetics, 105:295–300.Swan GE (1999) Implications of genetic epidemiology for the prevention oftobacco use. Nicotine and Tobacco Research, 1(Suppl. 1):S49–S56.Swan GE, Carmelli D (1995) Characteristics associated with excessive weight gainafter smoking cessation in men. American Journal of Public Health, 85:73–77.Swan GE, Carmelli D, Cardon LR (1996) The consumption of tobacco, alcohol,and coffee in Caucasian male twins: a multivariate genetic analysis. Journalof Substance Abuse, 8:19–31.Swan GE, Carmelli D, Cardon LR (1997) Heavy consumption of cigarettes,alcohol and coffee in male twins. Journal of Studies on Alcohol, 58:182–190.Szeto CY y colab. (2001) Association between mu-opioid receptor gene polymorphismsand Chinese heroin addicts. Neuroreport, 12:1103–1106.Tanaka F y colab. (1997) Polymorphism of alcohol-metabolizing genes affectsdrinking behavior and alcoholic liver disease in Japanese men. Alcoholism:Clinical and Experimental Research, 21:596–601.Thomasson HR y colab. (1994) Low frequency of the ADH2*2 allele amongAtayal natives of Taiwan with alcohol use disorders. Alcoholism: Clinical andExperimental Research, 18:640–643.165
NEUROCIENCIA DEL CONSUMO Y DEPENDENCIA DE SUSTANCIAS PSICOACTIVASTiihonen J y colab. (2000) CYP2A6 genotype and smoking. MolecularPsychiatry, 5:347–348.Tritto T y colab. (2001) Potential regulation of nicotine and ethanol actions byalpha4-containing nicotinic receptors. Alcohol, 24:69–78.True WR y colab. (1996) Models of treatment seeking for alcoholism: the role of genesand environment. Alcoholism: Clinical and Experimental Research, 20:1577–1581.True WR y colab. (1999) Common genetic vulnerability for nicotine and alcoholdependence in men. Archives of General Psychiatry, 56:655–661.Tsuang MT y colab. (1996) Genetic influences on DSM-III-R drug abuse anddependence: a study of 3,372 twin pairs. American Journal of Medical Genetics,67:473–477.Tsuang MT y colab. (1999) Genetic and environmental influences on transitionsin drug use. Behavior Genetics, 29:473–479.Tsuang MT y colab. (2001) The Harvard Twin Study of Substance Abuse: whatwe have learned. Harvard Review of Psychiatry, 9:267–279.Tyndale RF, Sellers EM (2002) Genetic variation in CYP2A6-mediated nicotinemetabolism alters smoking behavior. Therapeutic Drug Monitoring, 24:163–171.Tyndale RF, Droll KP, Sellers EM (1997) Genetically deficient CYP2D6 metabolismprovides protection against oral opiate dependence. Pharmacogenetics,7:375–379.Tyndale RF y colab. (2002) CYP2A6 lower activity genotypes are associated withdecreased risk for smoking and varying frequency among ethnic groups. En:Microsomes and drug oxidations. Sapporo, Japón: Simposio Internacional sobreMicrosomas y Oxidaciones de Fármacos: 150.Uchtenhagen A (2000a) Determinanten für drogenkonsum und –abhängigkeit.[Determinantes de uso de drogas y adicciones.] En: Uchtenhagen A,Zieglgänsberger W, eds. Suchtmedizin: konzepte, strategien und therapeutschesmanagement. [Medicina de las adicciones: conceptos, estrategias y manejo terapéutico.]Munich, Urban y Fischer Verlag: 193–195.Uchtenhagen A (2000b) Risikofaktoren und schutzfaktoren: eine übersicht.[Factores protectores y de riesgo: un panorama general.] En: Uchtenhagen A,Zieglgänsberger W, eds. Suchtmedizin: konzepte, strategien und therapeutschesmanagement. [Medicina de las adicciones: conceptos, estrategias y manejo terapéutico.]Munich, Urban y Fischer Verlag: 195–198.Ueno Y y colab. (1996) Effect of the cytochrome P450IIE1 genotype on ethanolelimination rate in alcoholics and control subjects. Alcoholism: Clinical andExperimental Research, 20(Suppl. 1):A17–A21.Uhl GR y colab. (1998) Dopaminergic genes and substance abuse. Advances inPharmacology, 42:1024–1032.Vaccarino FJ (1994) Nucleus accumbens dopamine-CCK interactions in psychostimulantreward and related behaviors. Neuroscience and BiobehavioralReviews, 18:207–214.Vandenbergh DJ y colab. (1997) High-activity catechol-O-methyltransferaseallele is more prevalent in polysubstance abusers. American Journal of MedicalGenetics, 74:439–442.166
- Page 136 and 137: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 138 and 139: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 140 and 141: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 142 and 143: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 144 and 145: 4. PSICOFARMACOLOGÍA DE LA DEPENDE
- Page 146 and 147: Capítulo 5Bases Genéticas de lasF
- Page 148 and 149: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 150 and 151: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 152 and 153: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 154 and 155: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 156 and 157: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 158 and 159: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 160 and 161: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 162 and 163: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 164 and 165: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 166 and 167: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 168 and 169: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 170 and 171: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 172 and 173: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 174 and 175: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 176 and 177: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 178 and 179: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 180 and 181: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 182 and 183: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 184 and 185: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 188 and 189: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 190 and 191: Capítulo 6Trastornos ConcurrentesI
- Page 192 and 193: 6. TRASTORNOS CONCURRENTES3. El uso
- Page 194 and 195: 6. TRASTORNOS CONCURRENTESy Meador-
- Page 196 and 197: 6. TRASTORNOS CONCURRENTESprobablem
- Page 198 and 199: 6. TRASTORNOS CONCURRENTESde drogas
- Page 200 and 201: 6. TRASTORNOS CONCURRENTESy Turski,
- Page 202 and 203: 6. TRASTORNOS CONCURRENTESEl víncu
- Page 204 and 205: 6. TRASTORNOS CONCURRENTESAlcohol y
- Page 206 and 207: 6. TRASTORNOS CONCURRENTESSerotonin
- Page 208 and 209: 6. TRASTORNOS CONCURRENTESFunción
- Page 210 and 211: 6. TRASTORNOS CONCURRENTESRECUADRO
- Page 212 and 213: 6. TRASTORNOS CONCURRENTEStos psiqu
- Page 214 and 215: 6. TRASTORNOS CONCURRENTESCarol G y
- Page 216 and 217: 6. TRASTORNOS CONCURRENTESdepressio
- Page 218 and 219: 6. TRASTORNOS CONCURRENTESHall RG y
- Page 220 and 221: 6. TRASTORNOS CONCURRENTESKapur S,
- Page 222 and 223: 6. TRASTORNOS CONCURRENTESMansvelde
- Page 224 and 225: 6. TRASTORNOS CONCURRENTESPetty F (
- Page 226 and 227: 6. TRASTORNOS CONCURRENTESSevy S y
- Page 228: 6. TRASTORNOS CONCURRENTESlesions o
- Page 231 and 232: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 233 and 234: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 235 and 236: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
NEUROCIENCIA DEL CONSUMO Y DEPENDENCIA DE SUSTANCIAS PSICOACTIVASTiihonen J y colab. (2000) CYP2A6 genotype and smoking. MolecularPsychiatry, 5:347–348.Tritto T y colab. (2001) Potential regulation of nicotine and ethanol actions byalpha4-containing nicotinic receptors. Alcohol, 24:69–78.True WR y colab. (1996) Mo<strong><strong>de</strong>l</strong>s of treatment seeking for alcoholism: the role of genesand environment. Alcoholism: Clinical and Experimental Research, 20:1577–1581.True WR y colab. (1999) Common genetic vulnerability for nicotine and alcohol<strong>de</strong>pen<strong>de</strong>nce in men. Archives of General Psychiatry, 56:655–661.Tsuang MT y colab. (1996) Genetic influences on DSM-III-R drug abuse and<strong>de</strong>pen<strong>de</strong>nce: a study of 3,372 twin pairs. American Journal of Medical Genetics,67:473–477.Tsuang MT y colab. (1999) Genetic and environmental influences on transitionsin drug use. Behavior Genetics, 29:473–479.Tsuang MT y colab. (2001) The Harvard Twin Study of Substance Abuse: whatwe have learned. Harvard Review of Psychiatry, 9:267–279.Tyndale RF, Sellers EM (2002) Genetic variation in CYP2A6-mediated nicotinemetabolism alters smoking behavior. Therapeutic Drug Monitoring, 24:163–171.Tyndale RF, Droll KP, Sellers EM (1997) Genetically <strong>de</strong>ficient CYP2D6 metabolismprovi<strong>de</strong>s protection against oral opiate <strong>de</strong>pen<strong>de</strong>nce. Pharmacogenetics,7:375–379.Tyndale RF y colab. (2002) CYP2A6 lower activity genotypes are associated with<strong>de</strong>creased risk for smoking and varying frequency among ethnic groups. En:Microsomes and drug oxidations. Sapporo, Japón: Simposio Internacional sobreMicrosomas y Oxidaciones <strong>de</strong> Fármacos: 150.Uchtenhagen A (2000a) Determinanten für drogenkonsum und –abhängigkeit.[Determinantes <strong>de</strong> uso <strong>de</strong> drogas y adicciones.] En: Uchtenhagen A,Zieglgänsberger W, eds. Suchtmedizin: konzepte, strategien und therapeutschesmanagement. [Medicina <strong>de</strong> las adicciones: conceptos, estrategias y manejo terapéutico.]Munich, Urban y Fischer Verlag: 193–195.Uchtenhagen A (2000b) Risikofaktoren und schutzfaktoren: eine übersicht.[Factores protectores y <strong>de</strong> riesgo: un panorama general.] En: Uchtenhagen A,Zieglgänsberger W, eds. Suchtmedizin: konzepte, strategien und therapeutschesmanagement. [Medicina <strong>de</strong> las adicciones: conceptos, estrategias y manejo terapéutico.]Munich, Urban y Fischer Verlag: 195–198.Ueno Y y colab. (1996) Effect of the cytochrome P450IIE1 genotype on ethanolelimination rate in alcoholics and control subjects. Alcoholism: Clinical andExperimental Research, 20(Suppl. 1):A17–A21.Uhl GR y colab. (1998) Dopaminergic genes and substance abuse. Advances inPharmacology, 42:1024–1032.Vaccarino FJ (1994) Nucleus accumbens dopamine-CCK interactions in psychostimulantreward and related behaviors. Neuroscience and BiobehavioralReviews, 18:207–214.Van<strong>de</strong>nbergh DJ y colab. (1997) High-activity catechol-O-methyltransferaseallele is more prevalent in polysubstance abusers. American Journal of MedicalGenetics, 74:439–442.166